CTLA4 and hepatocellular carcinoma: Clinical experience with checkpoint inhibitors in HCC includes early trials with the anti–cytotoxic T-lymphocyte-associated protein 4 agent tremelimumab and a large phase II trial with the anti–programmed cell death protein 1 agent nivolumab.